Review finds heart risk in anti-smoking drug Chantix

07/5/2011 | Reuters

A meta-analysis in the Canadian Medical Association Journal found that healthy, middle-age users of Chantix, Pfizer's smoking-cessation drug, had a 72% greater risk of heart problems requiring hospitalization compared with placebo users. Last month, the FDA said Chantix's warning label will be revised to mention increased cardiovascular risk in those with a history of heart disease. Pfizer is working with the agency "to conduct a combined analysis of clinical-trial data" that "will help further evaluate the cardiovascular safety of Chantix," the company said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX